| Similar Articles |
|---|
 |
Chemistry World
June 12, 2014
Andy Extance |
Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors.   |
Chemistry World
October 19, 2015
Philippa Matthews |
BMS agrees $1.7bn immuno-oncology collaboration Bristol-Myers Squibb has entered into a worldwide license and collaboration with Five Prime Therapeutics to develop and commercialize Five Prime's colony stimulating factor 1 receptor (CSF1R) antibodies. |
Chemistry World
August 5, 2015
Rebecca Trager |
Grabbing slices of the immuno-oncology pie An increasing number of companies are competing for a slice of the immuno-oncology market |
Chemistry World
July 8, 2014
Phillip Broadwith |
First of a new breed of anticancer antibodies approved in Japan Ono pharmaceuticals' Opdivo (nivolumab) has been approved for treating melanomas where surgery is impossible. |
Chemistry World
July 3, 2015
Andy Extance |
Pharma queues up for checkpoint inhibitor collaborations Amid fierce rivalries over the latest generation of cancer treatments, drug makers have been weaving a complex web of collaborations on combination therapies spanning much of the pharmaceutical industry. |
Chemistry World
August 27, 2014
Phillip Broadwith |
Clinical collaborations drive cancer immunotherapy A joint clinical trial agreement between Merck & Co and Pfizer is the latest in a rather tangled web of tie-ups between companies with cancer drugs that harness patients' immune systems. |
Chemistry World
April 4, 2013
Phillip Broadwith |
Amylin headquarters to close with further job losses Bristol-Myers Squibb has confirmed that it will be closing the site in San Diego, US, which was formerly the corporate headquarters of biotech firm Amylin. |
Chemistry World
December 20, 2013
Patrick Walter |
AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture. |
Pharmaceutical Executive
August 1, 2005
Joanna Breitstein |
Weathering the Storm Out from financial scandal, CEO Peter Dolan is steering Bristol-Myers Squibb's most productive pipeline yet. |
Pharmaceutical Executive
June 9, 2014 |
Immunotherapies: The New Hope for Cancer Treatment The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey |
Pharmaceutical Executive
November 1, 2014
Josh Baxt |
2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies. |
Chemistry World
July 3, 2012
Andrew Turley |
BMS and AstraZeneca buy Amylin for $7bn Pharma giants Bristol-Myers Squibb and AstraZeneca have teamed up to buy US biotech Amylin for $7 billion, further strengthening their position in the burgeoning market for diabetes drugs. |
Chemistry World
March 14, 2014
Phillip Broadwith |
Bristol-Myers Squibb to close Irish plant BMS tied the closure to 'changing market demand' for its products, along with efforts to optimize its manufacturing network. |
Chemistry World
October 7, 2015
Phillip Broadwith |
Bristol-Myers-Squibb fined for alleged Chinese bribes The US Securities and Exchange Commission has fined New York based pharmaceutical company Bristol-Myers Squibb over $14 million over alleged bribes made to Chinese state owned hospitals. |
Chemistry World
July 31, 2014
Phillip Broadwith |
AstraZeneca stocks respiratory and cancer pipelines AstraZeneca has agreed to buy Spanish firm Almirall's respiratory drug assets for $875 million up front, plus up to $1.2 billion in performance milestone payments. |
The Motley Fool
February 1, 2008
Brian Lawler |
Credit Crisis Bites Big Pharma Bristol-Myers Squibb takes a $275 million writedown in its investment portfolio for the quarter. |
Chemistry World
January 11, 2016
Phillip Broadwith |
GSK's ViiV to buy HIV drugs from BMS Bristol-Myers Squibb has agreed to sell its entire portfolio of investigational HIV drugs as the company seeks to exit research in virology. |
Chemistry World
November 3, 2015
Phillip Broadwith |
Bristol-Myers Squibb to buy Cardioxyl for heart drug The deal gives BMS full rights to develop CXL-1427, an experimental drug for acute decompensated heart failure, currently in Phase II clinical trials. |
